MAPK通路基因变异对mCRC一线FOLFIRI联合贝伐珠单抗疗效的影响
本研究基于FIRE-3与TRIBE两项随机III期试验,纳入567例KRAS野生型转移性结直肠癌患者,分析MAPK通路5个单核苷酸多态性。发现MKNK1 rs8602 AA基因型携带者接受一线FOLFIRI联合贝伐珠单抗时无进展生存期更短,且在验证队列中客观缓解率更低;该关联在FOLFIRI联合西妥昔单抗对照组中未观察到。
要点
- KRAS野生型mCRC中,MKNK1 rs8602 AA型接受FOLFIRI/贝伐珠单抗者PFS更短。
- 验证队列中AA型客观缓解率低于任一C型携带者(25% vs 66%)。
- 该关联在FOLFIRI/西妥昔单抗对照组中未观察到。
核心结论
- MKNK1 rs8602多态性可能作为KRAS野生型mCRC患者一线FOLFIRI联合贝伐珠单抗的预测标志物。
- MKNK1可能成为药物开发的潜在靶点。
研究设计与样本
- 研究纳入FIRE-3和TRIBE两项随机III期试验中567例KRAS野生型mCRC患者,接受一线FOLFIRI/贝伐珠单抗(发现队列和验证队列)或FOLFIRI/西妥昔单抗(对照队列)。
- 分析MAPK信号通路中5个单核苷酸多态性。
主要发现
- 发现队列(FIRE-3)中,MKNK1 rs8602 AA基因型携带者接受FOLFIRI/贝伐珠单抗的中位PFS为7.9个月,任一C携带者为10.3个月(HR 1.73,P=0.038)。
- 验证队列(TRIBE)多变量分析中,AA携带者中位PFS为9.0个月,任一C携带者为11.0个月(HR 3.04,P=0.029)。
- 验证队列中AA携带者客观缓解率为25%,任一C携带者为66%(P=0.049)。
- 对照队列接受FOLFIRI/西妥昔单抗的AA基因型携带者未显示PFS缩短。
- 合并两个FOLFIRI/贝伐珠单抗队列后,AA携带者PFS为9.0个月,任一C携带者为10.5个月(单变量HR 1.74,P=0.015;多变量HR 1.76,P=0.022);客观缓解率AA携带者36%,任一C携带者65%(P=0.005)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The MAPK-interacting kinase 1 (MKNK1) is localized downstream of the RAS/RAF/ERK and the MAP3K1/MKK/p38 signaling pathway. Through phosphorylation MKNK1 regulates the function of eukaryotic translation initiation factor 4E, a key player in translational control, whose expression is often upregulated in metastatic colorectal cancer patients (mCRC). Preclinical data suggest that MKNK1 increases angiogenesis by upregulating angiogenic factors. We therefore hypothesize that variations in the MKNK1 gene predict outcome in mCRC patients treated with first-line FOLFIRI and bevacizumab (bev). PATIENTS AND METHODS: A total of 567 patients with KRAS wild-type mCRC in the randomized phase III FIRE-3 and TRIBE trials treated with first-line FOLFIRI/bev (discovery and validation cohorts) or FOLFIRI and cetuximab (cet) (control cohort) were included in this study. Five single-nucleotide polymorphisms in the MAPK signaling pathway were analyzed. RESULTS: AA genotype carriers of the MKNK1 rs8602 single-nucleotide polymorphism treated with FOLFIRI/bev in the discovery cohort (FIRE-3) had a shorter progression-free survival (PFS) than those harboring any C (7.9 versus 10.3 months, Hazard ratio (HR) 1.73, P = 0.038). This association could be confirmed in the validation cohort (TRIBE) in multivariable analysis (PFS 9.0 versus 11.0 months, HR 3.04, P = 0.029). Furthermore, AA carriers in the validation cohort had a decreased overall response rate (25% versus 66%, P = 0.049). Conversely, AA genotype carriers in the control group receiving FOLFIRI/cet did not show a shorter PFS. By combining both FOLFIRI/bev cohorts the worse outcome among AA carriers became more significant (PFS 9.0 versus 10.5 months) in univariable (HR 1.74, P = 0.015) and multivariable analysis (HR 1.76, P = 0.022). Accordingly, AA carriers did also exhibit an inferior overall response rate compared with those harboring any C (36% versus 65%, P = 0.005). CONCLUSION: MKNK1 polymorphism rs8602 might serve as a predictive marker in KRAS wild-type mCRC patients treated with FOLFIRI/bev in the first-line setting. Additionally, MKNK1 might be a promising target for drug development.
引用
- Berger MD, Stintzing S, Heinemann V, et al. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Ann Oncol. 2017. PMID: 29045529. doi:10.1093/annonc/mdx412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。